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DOSING PATTERNS OF ERYTHROPOIETIC AGENTS IN
ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Duh MS1, Lefebvre P2, Gosselin A2, Mody S3, McKenzie S4, Piech CT5
1Analysis Group Inc, Boston, MA, USA; 2Groupe d’Analyse, Ltee,
Montreal, QC, Canada; 3Ortho Biotech Clinical Affairs LLC, Apex,
NC, USA; 4Ortho Biotech Clinical Affairs LLC, Dallas,TX, USA;
5Ortho Biotech Clinical Affairs LLC, Bridgewater, NJ, USA
OBJECTIVES: Epoetin alfa (EPO) and darbepoetin alfa (DARB)
are approved for the treatment of anemia in patients with
chronic kidney disease (CKD) not on dialysis; however, little is
known about their dosing patterns in the elderly population. The
objective of this analysis was to evaluate the frequency of admin-
istration, dosage, and associated drug cost of EPO and DARB in
patients ≥65 years of age with CKD not on dialysis. METHODS:
A retrospective analysis was conducted using medical claims
from approximately 30 health plans during the period of July,
2002 through February, 2004. To be included in the analysis,
patients were required to be ≥65 years old, have ≥2 EPO or
DARB claims, have a CKD diagnosis and not be on dialysis, 
have no prior cancer diagnosis, and be newly treated with either
agent. 2003 wholesale acquisition costs (WAC) were used to cal-
culate drug costs. RESULTS: 149 EPO and 35 DARB patients
met the inclusion criteria. More males were in the EPO group
(54.4% vs. 34.3%, p = 0.03). Age was similar between the
groups (mean years; EPO 74.4 ± 5.3; DARB 74.4 ± 5.6, p =
0.96), as was average therapy duration (days; EPO 86.7 ± 86.5;
DARB 81.2 ± 78.8, p = 0.73). Weekly and extended (≥Q2W)
dosing regimens were found in both groups (EPO—QW: 40.3%,
Q2W: 40.3%, ≥Q3W: 19.5%; DARB—QW: 14.3%, Q2W:
54.3%, ≥Q3W: 31.4%). The average time interval between drug
administrations was 13.0 ± 6.9 days for the EPO group and 15.6
± 5.4 days for the DARB group. The average weighted weekly
dose was 11,121 ± 10,773 Units for EPO and 46.0 ± 29.9mcg
for DARB, corresponding to an average weekly drug cost of
$124 for EPO and $184 for DARB. CONCLUSION: Extended
dosing (≥Q2W) of EPO and DARB was identiﬁed in a majority
of elderly anemic CKD patients not on dialysis, with lower drug
acquisition costs observed in the EPO group compared to the
DARB group.
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PREVALENCE, DEMOGRAPHICS,AND PHARMACOLOGICAL
TREATMENT PATTERNS OF OVERACTIVE BLADDER IN A
MANAGED CARE POPULATION
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INTRODUCTION: This was a retrospective database study to
identify prescription treatment patterns for OAB in a managed
care population. METHODS: The two-year intake period was
January 1, 2001 to December 31, 2002. Members with ≥1 diag-
nosis code for OAB in medical claims and/or ≥1 prescription
claim for an OAB drug were included. All claims were collected
1 year pre- and ≥1 year post-index. RESULTS: A study cohort
of 19,486 OAB patients was identiﬁed, representing a 2% preva-
lence rate. The population was predominantly female (66%);
mean age was 56 years. Most (86%) were new OAB cases. Long-
acting OAB antimuscarinic medications were most frequently
prescribed. Among new OAB patients, 30% had ≥1 OAB-related
prescription claim(s) during follow-up. Only 9% of new OAB
patients were initiated on OAB therapy after index date; mean
time to initiation was 137 days (median 50 days). Most new
OAB patients (96%) discontinued all OAB medication; mean
time to discontinue was approximately two-months (median
one-month). Few patients were continuously on OAB therapy
(4%), switched, or added on a drug other than the initial OAB
drug (15%). CONCLUSIONS: There appears to be lack of phar-
macological intervention in OAB patients. Overall, patients were
slow to initiate treatment, remained on drug therapy brieﬂy, 
and most discontinued treatment. This may reﬂect intolerance 
of OAB pharmacological options and/or lack of efﬁcacy, non-
pharmacological management, a perception among patients
and/or physicians that OAB symptoms have little impact on
quality of life, or OAB patients may wait until symptoms become
severe before requesting treatment.
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EVALUATION OF THE RELIABILITY AND VALIDITY OF THE
INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE (I-QOL)
IN PATIENTS WITH DETRUSOR HYPERREFLEXIA
Barron R1, Slaton T2, Kozma C3, Reese P4
1Allergan Corp, Irvine, CA, USA; 2Independent Consulant, West
Columbia, SC, USA; 3Independent Consultant, West Columbia, SC,
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OBJECTIVES: The Incontinence Quality of life Questionnaire
(I-QOL) is a 22-item questionnaire used in patients with urinary
incontinence. Validity of the I-QOL has been demonstrated in
stress incontinence patients. The purpose of this study is to assess
I-QOL in patients with detrusor hyperreﬂexia. METHODS:
Data were from a multicenter, double-blind, randomized,
placebo-controlled, parallel group study of two Botox doses. The
I-QOL was scored according to the developer’s guidelines which
provide total score and three domain scores: avoidance and lim-
iting behavior (ALB), psychosocial impact (PS), social embar-
rassment (SE). Validity and reliability were assessed by item to
scale correlations, similarity of means and variance, reliability
(Cronbach’s alpha), ﬂoor and ceiling effects, and correlations
with clinical measures. Responsiveness was assessed by evalua-
tion of I-QOL scores for all groups. RESULTS: The majority of
patients (n = 56) were Caucasian (93%) and male (59%). All but
four items of the 22 I-QOL items were more highly correlated
with their hypothesized scale than with competing scales;
however most of the items failed to meet a criterion of “two stan-
dard errors greater”. Item means and variances were similar for
the PS and SE domains. The ALB items exhibited similar vari-
ances; however range in means was somewhat larger. Cronbach’s
alpha ranged from 0.79 to 0.89 for domains and 0.93 for the
total. There was no signiﬁcant ﬂoor or ceiling effect. Moderate
correlations (0.18 to 0.37) existed between I-QOL scores and
clinical measures (e.g., number of involuntary losses of urine,
and urodynamic parameters). CONCLUSIONS: The validity of
the I-QOL in this neurogenic bladder population is supported.
The ALB domain was not as consistent since there was a mix of
detrusor hyperreﬂexia patients in this study and one question
may not be as relevant for some patients. Additional study in
larger samples is warranted.
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ESTABLISHING THE CONTENT VALIDITY OF THE URINARY
SENSATION SCALE (USS)
Brewster JL1, Guan Z2, Green HL1, Jumadilova Z2, Coyne KS1
1MEDTAP International, Inc, Bethesda, MD, USA; 2Pﬁzer, Inc, New
York, NY, USA
OBJECTIVES: Overactive bladder (OAB) is characterized by
symptoms of urinary urgency, with or without incontinence,
urinary frequency, and nocturia. Because urinary urgency is a
hallmark symptom of OAB, it is necessary to accurately assess
its impact on patients. To this end, we assessed the content valid-
ity of the newly developed Urinary Sensation Scale (USS) for
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OAB. METHODS: The USS is a ﬁve-point rating scale of urinary
urgency that is completed at the time of each micturition. A
survey was mailed to urologists and gynecologists that asked
them to review the USS and complete the evaluation items. OAB
patients were recruited through an advertisement in a newspa-
per to participate in a one-time qualitative interview (cognitive
debrieﬁng). Patients were screened to ensure the presence of OAB
symptoms. Patients reviewed the USS and various wording and
response options. Patients were then cognitively debriefed using
standardized questions to determine their interpretation of the
scale, their understanding of urinary urgency, and the ease with
which the USS could be completed. RESULTS: Five physicians
completed the mail surveys. Twelve patients with a mean age of
53 (67% women) were cognitively debriefed. The physicians and
patients reported that the USS was appropriate, relevant, and
understandable. The patients found the deﬁnition of urinary
urgency to be clear and easy to comprehend, and they were able
to discriminate among the response options describing urinary
urgency. Patients denied having problems completing the USS
after each micturition. CONCLUSIONS: Overall, the physicians
and patients found the USS to be easy to understand and rele-
vant to urinary urgency. Content validity was established for the
USS.
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PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A
RETROSPECTIVE OAB STUDY
Del Aguila MA1, Harris HM1, Beaulieu JF1, Boccuzzi SJ1,
Jumadilova Z2,Wagner S3
1Aetna Health Information Solutions, Blue Bell, PA, USA; 2Pﬁzer, Inc,
New York, NY, USA; 3Pﬁzer, Inc, Aubrey,TX, USA
OBJECTIVE: To evaluate the impact of patient selection crite-
ria on baseline characteristics and selected outcomes in a cohort
of patients with overactive bladder (OAB). METHODS: Newly
diagnosed OAB patients were identiﬁed from a medical and
pharmacy claims database including more than 30 geographi-
cally diverse managed care plans. Two patient cohorts were com-
pared for baseline characteristics, treatment status, and incidence
of selected urologic conditions following diagnosis. The ﬁrst
group required only one claim with an OAB diagnosis (DX1);
the second required a conﬁrmatory claim (DX2). RESULTS: A
total of 113,061 DX1 and 39,863 DX2 patients were identiﬁed.
Mean ages for DX1 men and women were 60y and 52y, respec-
tively; mean ages for DX2 men and women were 57y and 49y,
respectively. In total, 28% of DX2 patients and 10% of DX1
patients received pharmacologic treatment. Of those untreated,
49% were men in DX2 group and 41% in DX1 group. In total,
26% of DX2 women and 20% of DX1 women had baseline uro-
logic infections, and 17% of DX2 women and 12% of DX1
women had baseline urologic disorders. A total of 11% of DX2
men and 9% of DX1 men had baseline urologic infections, and
28% of DX2 men and 21% of DX1 men had baseline benign
prostatic hyperplasia. In DX2 patients, the adjusted odds of
urinary tract infection was 0.77 (95% CI, 0.73–0.80); in DX1
patients, the same estimate was 1.19 (95% CI, 1.14–1.24).
CONCLUSIONS: Patients with one OAB diagnostic claim dif-
fered in demographic and clinical characteristics from those with
a conﬁrmatory claim. Furthermore, differences in percentages of
patients receiving OAB treatment may suggest that health-
seeking behaviors differ among patients with one and two diag-
nostic claims. These data support the use of a conﬁrmatory
diagnostic claim in some studies of OAB.
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DEGREE OF SYMPTOM BOTHER IN URINARY 
INCONTINENCE
Girts TK1, Fultz N2, Sternfeld B3, Pohl G4, Kinchen K4
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OBJECTIVES: Previous studies report that women with urge
urinary incontinence (UUI) symptoms are more bothered than
women with stress urinary incontinence (SUI) symptoms.
However, studies have not examined the relative bother of stress
and urge symptoms among women who experience both.
METHODS: A survey was mailed to 5130 women using a
national access panel and 3562 (69%) questionnaires were com-
pleted. Our analysis focuses on women with symptoms of both
SUI and UUI in the previous seven days. Women were asked
which type of symptom they would most like to get rid of. 
Frequency was categorized as stress predominant (more stress
leakages than urge leakages), equal, or urge predominant. Inter-
ference with everyday life was rated on a scale from zero “not
at all” to ten “a great deal.” RESULTS: In total, 3364 ques-
tionnaires met study criteria (age 18–60 and not pregnant); 359
(11%) women reported both types of UI symptoms, 162 stress
predominant, 146 equal frequency, and 51 urge predominant. In
women with equal frequency, 44% desired most to be rid of
stress symptoms, and 56% urge symptoms (p = 0.15 vs. alter-
native of no preference). Among stress predominant women,
62% most desired to be rid of stress symptoms while 76% of
urge predominant women most desired to be rid of urge symp-
toms (p < 0.0001). Interference with everyday life was 4.6 (3.2
SD) for stress symptoms and 4.8 (3.2 SD) for urge symptoms.
CONCLUSIONS: Among women with mixed incontinence
symptoms, relative bother of SUI and UUI is dependent on fre-
quency and types of leakages. Majority of women desired to be
rid of the symptom with the higher frequency. Interference with
daily activities is not signiﬁcantly different for the two types of
symptoms. This emphasizes importance of physicians assessing
mixed patients for symptom predominance and targeting the
more bothersome type of UI for initial treatment.
